Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last kr114.20 SEK
Change Today 0.00 / 0.00%
Volume 975.3K
As of 11:29 AM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

swedish orphan biovitrum ab (SOBI) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/11/15 - kr145.90
52 Week Low
10/16/14 - kr65.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

swedish orphan biovitrum ab (SOBI) Related Businessweek News

No Related Businessweek News Found

swedish orphan biovitrum ab (SOBI) Details

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of inflammation, and genetics and metabolism diseases primarily in Europe and North America. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; Xiapex for the treatment of Peyronie’s disease; and Yondelis for the treatment of a type of cancer. The company also offers Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases. In addition, it provides Aloxi, Betapred, ChondroCelect, Collatamp, Cometriq, Defibrotide, Erwinase, Ferriprox, Fosinopril, Kepivance, Megestrol, Ruconest, and Willfact for the treatment of rare diseases. Further, the company’s rFVIIIFc and rFIXFc are development projects in pipeline for the treatment of hemophilia; Kiobrina, which is under Phase III clinical trials to enhance growth in premature infants; and SOBI002 is in Phase I clinical trials. It also manufactures drug substance for ReFacto AF/XYNTHA for the treatment of hemophilia A. The company has an agreement with Auxilium Pharmaceuticals for the development, supply, and commercialization of Xiapex, a biologic for the treatment of Dupuytren’s contracture. Swedish Orphan Biovitrum AB (publ) is headquartered in Stockholm, Sweden.

648 Employees
Last Reported Date: 07/16/15

swedish orphan biovitrum ab (SOBI) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr5.4M
Compensation as of Fiscal Year 2014.

swedish orphan biovitrum ab (SOBI) Key Developments

Selexis Signs Service Agreement with Sobi

Selexis announced it has signed a service agreement with Swedish Orphan Biovitrum AB or Sobi. No financial terms were announced. Under the terms of the agreement, Selexis will use its own libraries to help Sobi in the discovery of difficult-to-express proteins.

Sobi Opens European and Benelux Office in Brussels

Sobi formally opened its new European and Benelux office in Brussels, Belgium. The Brussels office will act as an operational hub for Sobi's business and is consistent with the strategic importance of Europe for Sobi, representing approximately 60% of the company's global annual product sales. The office will also enable additional focus on the business in the Benelux region. The opening of the new office in Brussels is a next step in Sobi's mission to develop and deliver innovative therapies and services to improve the lives of patients living with rare diseases. With more than 600 employees and offices in 24 different countries, Sobi currently delivers therapies to patients in 67 countries across the globe. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases, and two of the company's Haemophilia treatments in development are currently being reviewed by the European Medicines Agency.

Biogen and Swedish Orphan Biovitrum AB (publ) Announce the Interim Results of Phase 3, Open-Label Extension Study Called ASPIRE

Biogen and Swedish Orphan Biovitrum AB (publ) announced the interim results of Phase 3, open-label extension study called ASPIRE were published in the online edition of Haemophilia, the journal of the World Federation of Hemophilia, the European Association for Haemophilia and Allied Disorders, and the Hemostasis & Thrombosis Research Society. Study participants completing the Phase 3 A-LONG and Kids A-LONG studies were eligible to participate in ASPIRE. The results to-date show the majority of participants in ASPIRE, maintained or extended their dosing intervals between treatments compared to the A-LONG and Kids A-LONG studies. As of the interim analysis, the median time in the ASPIRE study was 80.9 weeks for adults and adolescents completing the A-LONG study, and 23.9 weeks for children completing the Kids A-LONG study. Inhibitor development is the primary endpoint of ASPIRE and no inhibitors were reported in any treatment groups. Through the interim ASPIRE analysis, adults and adolescents experienced annualized bleeding rates (ABRs) of 0.66, 2.03 and 1.97 in the individualized, weekly and modified prophylaxis arms, respectively. Children on individualized prophylaxis also experienced low bleeding rates, with an overall median ABR of 0.0 in children less than 6 years of age, and 1.54 for children ages 6 to 12. These results were consistent with data from the Phase 3 A-LONG and Kids A-LONG studies. In addition to efficacy and safety endpoints, the publication also reports changes in prophylactic infusion frequency from the end of the A-LONG study through the interim analysis. Of the adults and adolescents who had previously been treated prophylactically and who remained in the study through the interim analysis (n=128), 72% maintained their prophylactic dosing interval and 22% lengthened and 6% shortened the time between infusions. Extension study participants could change treatment group at any time. In ASPIRE, most participants received prophylactic treatment and were able to maintain protection against bleeding episodes with ELOCTATE consumption that was consistent with that observed in A-LONG and Kids A-LONG.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SOBI:SS kr114.20 SEK 0.00

SOBI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €11.13 EUR -0.035
Oxford Biomedica PLC 7.54 GBp -0.11
Veloxis Pharmaceuticals A/S kr1.51 DKK +0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation SOBI Industry Range
Price/Earnings 100.0x
Price/Sales 10.3x
Price/Book 6.7x
Price/Cash Flow 209.2x
TEV/Sales 9.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SWEDISH ORPHAN BIOVITRUM AB, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at